Anatara Lifesciences Ltd (ANR.AX)

AUD 0.05

(0.0%)

Market Cap (In AUD)

10.6 Million

Revenue (In AUD)

-

Net Income (In AUD)

-1.45 Million

Avg. Volume

142.74 Thousand

Currency
AUD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.021-0.073
PE
-
EPS
-
Beta Value
0.806
ISIN
AU000000ANR0
CUSIP
Q0R25K109
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. David Lionel Brookes F.A.C.I.D., FACRRM, FAICD, MBBS
Employee Count
-
Website
https://anataralifesciences.com
Ipo Date
2014-10-15
Details
Anatara Lifesciences Limited engages in the research, development, and commercializing of evidence-based solutions for gastrointestinal diseases in animals and humans in Australia. It offers Gastrointestinal ReProgramming, a proprietary formulation that combines bromelain with other evidence-based ingredients to address the primary underlying factors associated with human gastrointestinal conditions, such as irritable bowel syndrome and inflammatory bowel disease; and 3FDC for the treatment of anxiety, stress, or depression. The company also provides Detach for the treatment of diarrhea disease in piglets; BONIFF, a revised formulation to dry feed for piglets after weaning; and ANR-pf, a proprietary formulation for poultry water. Anatara Lifesciences Limited was incorporated in 2010 and is based in Carlton, Australia.